Response to: 'Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results'.

Published

Journal Article (Letter)

Full Text

Duke Authors

Cited Authors

  • Homer, N; Grewal, DS; Mirza, RG; Lyon, AT; Gill, MK

Published Date

  • December 2015

Published In

Volume / Issue

  • 29 / 12

Start / End Page

  • 1630 - 1631

PubMed ID

  • 26449193

Pubmed Central ID

  • 26449193

Electronic International Standard Serial Number (EISSN)

  • 1476-5454

Digital Object Identifier (DOI)

  • 10.1038/eye.2015.191

Language

  • eng

Conference Location

  • England